235 related articles for article (PubMed ID: 15490267)
1. Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment.
Miki T; Nakatsuka K; Naka H; Masaki H; Imanishi Y; Ito M; Inaba M; Morii H; Nishizawa Y
J Bone Miner Metab; 2004; 22(6):569-76. PubMed ID: 15490267
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure.
Jiang Y; Zhao JJ; Mitlak BH; Wang O; Genant HK; Eriksen EF
J Bone Miner Res; 2003 Nov; 18(11):1932-41. PubMed ID: 14606504
[TBL] [Abstract][Full Text] [Related]
3. A small dose of human parathyroid hormone(1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis.
Sone T; Fukunaga M; Ono S; Nishiyama T
Miner Electrolyte Metab; 1995; 21(1-3):232-5. PubMed ID: 7565456
[TBL] [Abstract][Full Text] [Related]
4. Human parathyroid hormone (1-34) increases mass and structure of the cortical shell, with resultant increase in lumbar bone strength, in ovariectomized rats.
Arita S; Ikeda S; Sakai A; Okimoto N; Akahoshi S; Nagashima M; Nishida A; Ito M; Nakamura T
J Bone Miner Metab; 2004; 22(6):530-40. PubMed ID: 15490262
[TBL] [Abstract][Full Text] [Related]
5. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.
Chen P; Miller PD; Recker R; Resch H; Rana A; Pavo I; Sipos AA
J Bone Miner Res; 2007 Aug; 22(8):1173-80. PubMed ID: 17451369
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic agents for disorders of bone and calcium metabolism. Development of nasal formulation of hPTH (1-34)].
Sato K
Clin Calcium; 2007 Jan; 17(1):64-71. PubMed ID: 17211095
[TBL] [Abstract][Full Text] [Related]
7. Human parathyroid hormone 1-34 prevents bone loss in experimental biliary cirrhosis in rats.
Dresner-Pollak R; Gabet Y; Steimatzky A; Hamdani G; Bab I; Ackerman Z; Weinreb M
Gastroenterology; 2008 Jan; 134(1):259-67. PubMed ID: 18061175
[TBL] [Abstract][Full Text] [Related]
8. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide.
Lindsay R; Cosman F; Zhou H; Bostrom MP; Shen VW; Cruz JD; Nieves JW; Dempster DW
J Bone Miner Res; 2006 Mar; 21(3):366-73. PubMed ID: 16491283
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
10. Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)(2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone.
Boyce RW; Paddock CL; Franks AF; Jankowsky ML; Eriksen EF
J Bone Miner Res; 1996 May; 11(5):600-13. PubMed ID: 9157775
[TBL] [Abstract][Full Text] [Related]
11. Intermittent administration of human parathyroid Hormone(1-34) prevents immobilization-related bone loss by regulating bone marrow capacity for bone cells in ddY mice.
Sakai A; Sakata T; Ikeda S; Uchida S; Okazaki R; Norimura T; Hori M; Nakamura T
J Bone Miner Res; 1999 Oct; 14(10):1691-9. PubMed ID: 10491216
[TBL] [Abstract][Full Text] [Related]
12. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.
Dempster DW; Cosman F; Kurland ES; Zhou H; Nieves J; Woelfert L; Shane E; Plavetić K; Müller R; Bilezikian J; Lindsay R
J Bone Miner Res; 2001 Oct; 16(10):1846-53. PubMed ID: 11585349
[TBL] [Abstract][Full Text] [Related]
13. Anabolic effects of recombinant human parathyroid hormone (1 - 84) and synthetic human parathyroid hormone (1 - 34) on the mandibles of osteopenic ovariectomized rats with maxillary molar extraction.
Kawane T; Takahashi S; Saitoh H; Okamoto H; Kubodera N; Horiuchi N
Horm Metab Res; 2002 Jun; 34(6):293-302. PubMed ID: 12173069
[TBL] [Abstract][Full Text] [Related]
14. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
15. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium.
Lindsay R; Zhou H; Cosman F; Nieves J; Dempster DW; Hodsman AB
J Bone Miner Res; 2007 Apr; 22(4):495-502. PubMed ID: 17227219
[TBL] [Abstract][Full Text] [Related]
16. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.
Iida-Klein A; Lu SS; Cosman F; Lindsay R; Dempster DW
Bone; 2007 Feb; 40(2):391-8. PubMed ID: 17056311
[TBL] [Abstract][Full Text] [Related]
17. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
Anastasilakis AD; Polyzos SA; Avramidis A; Papatheodorou A; Terpos E
Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
[TBL] [Abstract][Full Text] [Related]
18. [Bone histology in postmenopausal osteoporosis--variations in cellular activity].
Lozo P; Krpan D; Krvavica A; Vukelić Baturić T; Fistonić I; Kusec V
Acta Med Croatica; 2004; 58(1):5-11. PubMed ID: 15125387
[TBL] [Abstract][Full Text] [Related]
19. Study on preparation and activity of a novel recombinant human parathyroid hormone(1-34) analog with N-terminal Pro-Pro extension.
Chunxiao W; Jingjing L; Yire X; Min D; Zhaohui W; Gaofu Q; Xiangchun S; Xuejun W; Jie W; Taiming L
Regul Pept; 2007 Jun; 141(1-3):35-43. PubMed ID: 17300845
[TBL] [Abstract][Full Text] [Related]
20. [Morphologic study of iliac crest spongiosa in patients with osteoporosis treated with combination therapy of pulsatile administration of parathyroid hormone (1-38 hPTH) and sequential addition of calcitonin nasal spray].
Vogel M; Hesch RD; Delling G
Med Klin (Munich); 1990 Feb; 85(2):82-6. PubMed ID: 2319988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
